Analyst Scoreboard: 5 Ratings For Clene

In the preceding three months, 5 analysts have released ratings for Clene CLNN, presenting a wide array of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $6.6, a high estimate of $7.00, and a low estimate of $5.00. Witnessing a positive shift, the current average has risen by 1.54% from the previous average price target of $6.50.

Investigating Analyst Ratings: An Elaborate Study

A clear picture of Clene's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Clene. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Clene compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Clene's stock. This examination reveals shifts in analysts' expectations over time.

For valuable insights into Clene's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Clene analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind Clene

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).

Clene: A Financial Overview

Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.

Revenue Growth: Clene's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -31.78%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Clene's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -15178.08%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): Clene's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -125.52%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Clene's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -22.75%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: With a high debt-to-equity ratio of 7.61, Clene faces challenges in effectively managing its debt levels, indicating potential financial strain.

The Core of Analyst Ratings: What Every Investor Should Know

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.